
Sanyou Biopharmaceuticals is a high-tech biopharmaceutical company driven by the mission of “To make it easy to develop new drugs worldwide”. The company is committed to fundamentally addressing the key challenges at the source of innovative drug development. Powered by its AI-STAL and supported by Sanyou Al-Drug Accelerator(SAI-DA), Sanyou provides comprehensive, one-stop solutions for innovative drug discovery, with a particular focus on molecular discovery and selection. Sanyou Bio has been dedicated to developing a world-class innovative biological drug R&D hub and to working collaboratively with partners worldwide to accelerate the development of innovative therapeutics. Headquartered in Shanghai, China, Sanyou has established global business centers across Asia, North America, and Europe, forming an international business network. The company currently operates and has planned over 20,000 square meters of R&D and GMP facilities. Sanyou has established strong collaborations with more than 2,000 pharmaceutical and biotech companies worldwide, empowering over 1,200 new drug discovery and development projects. It has completed more than 50 collaboration projects, over 10 of which have advanced to IND approval and clinical development stages. The company has filed over 170 invention patents, with more than 30 granted. It has also obtained over 10 national and international qualifications and system certifications, including National High-Tech Enterprise, Shanghai “Specialized and Innovative” Enterprise, ISO9001, and ISO27001.
Sanyou Biopharmaceuticals의 시장 확장을 추적하고 있습니다
최근 90일간 시그널 3건.
Sanyou Biopharmaceuticals의 글로벌 확장이 경쟁사와 비교해 어떤지
막대는 비교 대상 회사 간 상대적 규모를 나타냅니다.
열5| 회사 | 시장 | 신규 시장 | 모멘텀 | 활동 | 확장 점수 |
|---|---|---|---|---|---|
Sanyou Biopharmaceuticals본 회사 | 0 | 0 | — | 0 | 0 |
Business Development And Licensing Director
공고 보기Belfast, Northern Ireland, United Kingdom · 5개월 전
진행 중인 캠페인이 없습니다
이 회사를 추적하고 변화가 생기는 즉시 알림을 받으려면 가입하세요.
삼우 바이오, Mrna Mab 혁신 항체 생성 기술 플랫폼 출시. mRNA 설계 및 면역화에 장점 제공.
삼우바이오가 10년에 걸쳐 개발한 AI-STAL 플랫폼은 방대한 분자 라이브러리와 첨단 기술 시스템으로 신약 발견을 혁신했습니다.
삼우 바이오 플랫폼은 10조 분자 용량을 특징으로 하며, 10개의 하위 플랫폼으로 다양한 분자 유형의 약물 R&D 효율성을 향상시킵니다.
인증된 이메일과 직통 전화 잠금 해제
무료 · 신용카드 불필요
Sanyou Biopharmaceuticals의 사업, 시장, 성장 시그널에 대한 빠른 답변입니다.

© 2026 Pubrio. 모든 권리 보유.